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Abstract
Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC
is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman.
Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better
than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9%
and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin,
epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different
subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in
membrane of cells ChRCC.
Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase
inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors
(sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating
research hypotheses which should be verified by prospective studies.
Epidemiology
Renal cell carcinoma (RCC) is rather a rare neoplasm (in
Poland about 3% of all tumors). According to the most
recent National Cancer Register in Poland, 2150 men and
1501 women were diagnosed with renal cancer in 2004
[1].
Approximately 200,000 new cases of RCC are diagnosed
annually worldwide, while the number of deaths caused
by RCC approaches 100,000. Cure can be obtained in 70-
90% of patients in the TNM stage I, in 55-70% of patients
in stage II, in 20-30% of patients in stage III, and in less
than 10% in stage IV [2].
The 2004 World Health Organization (WHO) classifica-
tion of RCC recognized several subtypes of RCC. Most
common subtypes are: clear cell RCC (70%), papillary
RCC (10-15%), chromophobe RCC (4-6%), collecting
duct carcinoma (about 1%) and unclassified RCC (4-5%)
[3,4].
Chromophobe RCC (ChRCC) is diagnosed mainly in 6th
decade of life. An incidence of ChRCC is similar in both
men and woman [5]. 86% of ChRCCs are diagnosed in
stage 1 or 2 [3]. Renal vein invasion is seen in about 5%
of cases [5].
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Incidence of metastatic disease in chromophobe renal cell
carcinoma is 6-7% [6,7].
In summary of 28 cases based on 7 reports, most common
metastatic sites were liver (39%) and lung (36%) [6].
Pathology
Chromophobe RCC was first described in patients by
Thoenes in 1985 [8].
Macroscopically, ChRCC is a solitary, circumscribed, and
not capsulated mass with a homogeneous light brown cut
surface. The median tumor size of ChRCC is 6.0 cm, and
it is larger than that of other subtypes [7].
Microscopically, it contains of large, polygonal cells with
prominent cell membrane [5]. Cytoplasm is pale and
resistant to staining with hematoxylin and eosin. ChRCC
cells have irregular nuclei with perinuclear clear halo. The
tumor blood vessels have thick walls and are eccentrically
hyalinized [3].
Chromophobe RCC is a heterogeneous group including
classic type, eosinophilic type and mixed type. Eosi-
nophilic variant (containing greater than 80% eosi-
nophilic cells) has areas similar to renal oncocytomas
(nested, alveolar or sheetlike architecture with eosi-
nophilic granularity, perinuclear clearing, peripheral
accentuation of cytoplasm) and it is often bilateral (11%)
and multifocal (22%). Classic type of chromophobe RCC
(containing greater than 80% pale cells) is associated with
necrosis or sarcomatoid change. It has alveolar or sheet-
like architecture and cytoplasm with flocculent "soap-
bubble" appearance. Chromophobe RCCs with mixed
histology have variable architecture (containing admix-
ture of pale and eosinophilic cells) [6].
Microscopic tumor necrosis and sarcomatoid change are
known to be aggressive with a high potential for distant
metastases [6].
One of the diagnostic criteria of ChRCC is Hale colloidal
iron [5], another are intracytoplasmatic microvesicles
between 250-400 nm in diameter [9] (Figure 1- Chromo-
phobe renal cell carcinoma, HE, 200×; Figure 2 - Positive
reaction showing the presence of colloidal iron in cyto-
plasm of ChRCC, 400×).
They can be demonstrated by electron microscopy, which
is not used routinely in diagnosis of chromophobe RCC.
The main diagnostic criteria of chromophobe RCC is mor-
phology coupled with characteristic immunophenotype
(diffuse CK7, and KIT positivity).
Variable expression patterns of cytokeratins (CK), vimen-
tin, epithelial membrane antigen (EMA), CD10 and par-
valbumin can be potentially helpful in diagnosis of
different subtypes of RCC. Vimentin was reported positive
in 0-21% of ChRCC, CD10 in 0-33% of ChRCC, CK7 in
60-100% of ChRCC, CK8 in 50% of ChRCC, CK18 in
100% of ChRCC, CK19 in 33% of ChRCC, CK20 in
12.5% of ChRCC, EMA 75-100% of ChRCC and parval-
bumin 100% of ChRCC. Sometimes ChRCC can be mis-
taken for renal oncocytoma [10,11] (Table 1).
Clinical and Histomorphological Features
Prognosis in ChRCC is better than in other types of RCC.
Five- and 10-year DFS for chromophobe RCC was 83.9%
Chromophobe renal cell carcinoma, HE, 200× Figure 1
Chromophobe renal cell carcinoma, HE, 200×.
Positive reaction showing the presence of colloidal iron in  cytoplasm of ChRCC, 400× Figure 2
Positive reaction showing the presence of colloidal 
iron in cytoplasm of ChRCC, 400×.Journal of Experimental & Clinical Cancer Research 2009, 28:134 http://www.jeccr.com/content/28/1/134
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and 77.9%, respectively [12]. The median time from
nephrectomy to metastasis detection, and from metastasis
detection to death were twice as long for ChRCC than for
other subtypes of RCC (papillary, clear cell RCC) [7].
In univariate analysis: sarcomatoid change (p < 0.001),
microscopic necrosis (p = 0.019), tumor size (p = 0.025),
pT stage (3.4 vs. 1.2; p = < 0.001), broad alveolar growth
(p = 0.012), vascular invasion (p = 0.020), and Fuhrman
nuclear grade (grade 4 vs.3 vs 2; p < 0.001) were associated
with aggressive ChRCC behavior. Independent predictors
(Multivariable Cox Regression) of aggressive ChRCC
included: pT stage (pT 3.4 vs. pT 1.2; p = 0.025, relative
hazard 3.4), sarcomatoid change (p = 0.013, relative haz-
ard 4.7) and microscopic necrosis (p = 0.020, relative haz-
ard 3.5) [6]. Other factors like: age, sex, histologic
subtyping by clear, eosinophilic or mixed cell types, tubu-
locystic pattern, degenerate or symplastic atypia were not
predictors of chromophobe RCC behavior.
The patients with aggressive phenotype of chromophobe
RCC may be candidates for adjuvant therapies as they
become available [6].
ChRCCs are hyperechogenic in ultrasound examination,
CT imaging or MRI demonstrate homogeneous enhance-
ment. A spoke-wheel pattern of contrast enhancement is
characteristic for ChRCC and for onkocytoma [13]. Most
of ChRCCs are sporadic, but sometimes they are associ-
ated with BHD (Birt-Hogg-Dubè) syndrome [14].
Genetic Syndrome associated with 
chromophobe RCC
BHD syndrome is an autosomal dominant disorder that
includes: benign skin tumor (skin tags, fibrofolliculo-
mas), renal epithelial neoplasms (ChRCC, oncocytoma)
and spontaneous pneumothorax. Renal tumors are often
multifocal and bilateral. BHD gene encodes potential
tumor suppressor protein - folliculin on 17p11 [15].
ChRCCs is characterized by length polymorphism such as
loss of chromosomal material involving chromosomes: 1,
2, 3p, 6, 10, 13, 17p, 17q and 21 [16,17]. It may be help-
ful in distinguishing between clear, papillary and chromo-
phobe subtypes of RCC.
Expression of CD117 (KIT)
KIT (CD117) is a type III receptor tyrosine kinase that
plays a role in intracellular signal transduction in several
cell types. It regulates apoptosis, cell differentiation, pro-
liferation, chemotaxis, and adhesion. Pathologic activa-
tion of KIT through gain-of-function mutations leads to
neoplasia of KIT-dependent and KIT-positive cell types in
different systems: Cajal cells - gastrointestinal stromal
tumors (GISTs), myeloid cells - myeloid leukemia. In
addition, many tumors have positive KIT immunoreactiv-
ity: small cells carcinomas, adenoid cystic carcinoma,
chromophobe, thymic and sometimes ovarian and breast
carcinomas [18].
In normal tissue of kidney KIT showed weak immunore-
activity only in the cytoplasm of distal tubules [19]. From
all RCCs, KIT gene product was detected (overexpression)
in membrane of cells ChRCC (88-100%) [19,20]. This is
in agreement with histogenetic origin of chromophobe
RCC from distal tubules.
KIT expression in classic variant is more often than eosi-
nophilic variant (82% vs. 67%) [21].
Thus, immunohistochemical detection of KIT expression
appears to be useful in diagnosis and treatment of
ChRCC.
Yamazaki et al. reported upregulation of c-kit gene expres-
sion in ChRCCs. The mechanism for the overexpression of
KIT in ChRCC is unknown. They suggested that the KIT
signal pathway in ChRCCs could be activated in an auto-
Table 2: Targets for Imatinib, Dasatinib and Nilotinib
Target spectrum Imatinib Dasatinib Nilotinib
BCR-ABL + + +
PDGFR + + +
c-KIT + + +
Src family kinases - + -
Ephrin receptor kinases - + only EphB4
NQO2 + - +
DDR1 + + +
CSF-1R - - +
Table 1: Expression of immunohistological markers of ChRCC
Immunohistological markers of ChRCC CK
7
CK
8
CK
18
CK
19
CK
20
Vimentin EMA CD10 Parvalbumin
Positive reactivity (%) 60-100 50 100 33 12.5 0-21 75-100 0-33 100Journal of Experimental & Clinical Cancer Research 2009, 28:134 http://www.jeccr.com/content/28/1/134
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crine way [19]. In summary 70 cases, based on 4 reports
investigators were unable to detect activating mutations
within exon 17 of the c-kit gene [19-22]. Absence of c-kit
mutation could be argue for potential effectiveness of
imatinib therapy in patients with metastatic ChRCCs.
Potential targeted therapy for advanced ChRCC
Now we have three potentially active and targeted agents
against CD 117: imatinib, dasatinib and nilotinib.
Imatinib
as KIT tyrosine kinase inhibitor (TKI) is an accepted treat-
ment of chronic eosinophilic leukemia, hypereosi-
nophilic syndrome, chronic myeloid leukemia,
myelodysplastic/myeloproliferate syndrome, acute lym-
phoblastic leukemia, dermatofibrosarcoma protuberans,
gastrointestinal stromal tumors [18]. The targets for imat-
inib include: BCR/ABL, CD 117, PDGFRA (platelet-
derived growth factor receptor) [23] and also DDR1 (dis-
coidin domain receptor 1), NQO2 (quinone reductase
QR2) [24,25].
Dasatinib
is a second-line multikinase (besides BCR/ABL kinase)
inhibitor. Dasatinib is used in patients with chronic mye-
loid leukemia or acute lymphoblastic leukemia with
resistance or intolerance of imatinib. In vitro, it has
approximately 325-fold greater potency than imatinib in
inhibition of BCR/ABL kinase [26]. In phase II trial, dasat-
inib increased response rates by > 2-fold versus high-dose
of imatinib. The targets for dasatinib include: BCR/ABL,
CD 117, PDGFRA, DDR1, DDR2, Src family kinases and
ephrin receptor kinases [24,27].
Nilotinib
is the result of modifications to the imatinib molecule
[28,29]. Nilotinib like imatinib, inhibits BCR/ABL, CD
117, PDGFRA, NQO2, DDR1 [24,25,29]. Nilotinib also
inhibits CSF-1R (colony-stimulating factor-1 receptor)
[30] and EphB4 (ephrin receptor) [31]. Nilotinib was 43-
60 times more potent than imatinib in cell lines (KBM5,
KBM7) [32].
A phase II clinical trial confirmed activity of nilotinib in
imatinib-resistant or imatinib-intolerant chronic myeloid
leukemia [33] (Table 2).
We realize that this treatment hypothesis is controversial.
Up to now, we have not found cases of successful treat-
ment in the literature. But we think, that prospective trials
with these agents in ChRCC should clarify their use in the
future.
Other interesting therapies for advanced ChRCC may
include therapies used in advanced clear cell renal carci-
noma (CCRCC). Both, sorafenib and sunitinib showed
clinical activity in randomized clinical trials in treatment
metastatic CCRCC [34,35]. These are tyrosine kinases
inhibitors including vascular endothelial growth factor
receptor (VEGFR) and platelet-derived growth factor
receptor (PDGFR) [36,37].
VEGF and PDGF are markers of angiogenesis which plays
an essential role in tumor growth and metastatization.
Overexpression VEGF and PDGF in RCCs is associated
with defective von Hippel-Lindau (VHL) protein. It can
induce the expression of the genes involving in angiogen-
esis through the hypoxia-inducible factor 1α (HIF-1α)
pathway. VHL is inactivated in up to 80% of sporadic
cases of clear-cell carcinoma [38].
ChRCC can be associated with high serum levels of VEGF,
making VEGF-targeted therapy an attractive therapeutic
option [39].
In biochemical and cellular tests both agents inhibit CD
117. They seem to be next potential targeted therapy for
advanced ChRCC [37].
Choueiri et al. confirmed, that sunitinib and sorafenib are
active agents in metastatic ChRCC: 75% of patients had
stable disease (SD) more than 3 months and 25% had
partial response (PR) [37] Table 3.
Conclusion
Currently, we do not have any effective treatment for the
metastatic disease apart from surgical procedures. Overex-
pression of CD117 on cellular membranes of ChRCC
could be a potential target for kinase inhibitors like: imat-
inib, dasatinib, nilotinib. The potential targets for other
kinase inhibitors (sunitinib and sorafenib) in ChRCC
seem to be VEGFR and PDGFR. In conclusion, these
observations are the basis for formulating research
Table 3: Activity Sorafenib and Sunitynib in ChRCC
Agent No. of patients Median PFS (months) Partial Response
No. of patients
Stable Disease
No. of patients
Sunitinib 7 8.9 1 6
Sorafenib 5 27.5 2 3Journal of Experimental & Clinical Cancer Research 2009, 28:134 http://www.jeccr.com/content/28/1/134
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hypotheses which should be verified in prospective stud-
ies.
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